MEDIMMUNE AND MEDAREX ENTER BROAD ANTIBODY AGREEMENT


Gaithersburg,  MD and Princeton,  NJ, June 13, 2000 -- MedImmune,  Inc. (NASDAQ:
MEDI) and Medarex, Inc. (NASDAQ:  MEDX) announced today that they have signed an
agreement to develop fully human antibodies to multiple antigens using Medarex's
HuMAb-Mouse(R) technology. Under the terms of the agreement,  MedImmune receives
an exclusive,  worldwide license for the use of Medarex's HuMAb-Mouse technology
for the development of antibodies against respiratory  syncytial virus (RSV) and
an option to further license the use of this technology for additional antigens.
Medarex  receives  technology  access  fees and could also  receive  license and
milestone payments, as well as royalties on product sales.

"We are excited about the opportunity to use Medarex's HuMAb-Mouse technology to
evaluate new antibodies for potential  product  development,"  said Dr. Wayne T.
Hockmeyer, MedImmune's chairman and chief executive officer.

"We are extremely  pleased to add  MedImmune to our growing list of  HuMAb-Mouse
partners,"  said Donald L.  Drakeman,  Medarex's  president and chief  executive
officer.  "MedImmune's proven product development  capabilities are a good match
for our HuMAb-Mouse technology."

Medarex is a  biopharmaceutical  company  developing  monoclonal  antibody-based
therapeutics  to  fight  cancer  and  other  life-threatening  and  debilitating
diseases.  Medarex has assembled a broad platform of patented  technologies  for
antibody  discovery  and  development,   including  the  HuMAb-Mouse(R)  and  TC
Mouse(TM)  systems for the creation of  high-affinity,  fully human  antibodies;
T-12  Development(TM)  offering the capability of moving from target to trial in
approximately  12  months;   and  Trans-Phage   Technology(TM)   combining  high
throughput screening with fully human antibody development.  Medarex creates and
develops fully human antibodies for itself and others,  offering a full range of
antibody   development   capabilities,   including   pre-clinical  and  clinical
manufacturing services. For more information about Medarex visit its web site at
www.medarex.com.

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  the  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

Except for the historical  information  presented,  certain matters discussed in
this press release are  forward-looking  statements  that are subject to certain
risks and  uncertainties  that could cause actual  results to differ  materially
from any future  results,  performance or  achievements  expressed or implied by
such  statements.  Such risks and  uncertainties  include risks  associated with
product discovery and development as well as risks detailed from time to time in
the companies' public disclosure  filings with the U.S.  Securities and Exchange
Commission  (SEC),  including each company's  Annual Report on Form 10-K for the
fiscal year ended December 31, 1999.  Copies of public  disclosure  filings with
the Securities and Exchange  Commission  (SEC) are available from each company's
investor relations  department.  There can be no assurance that such development
efforts  will  succeed,  that such  products  will receive  required  regulatory
clearance  or  that,  even if such  regulatory  clearance  were  received,  such
products would ultimately achieve commercial success.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereonto duly authorized.

                                 MEDIMMUNE, INC.
                                -----------------
                                  (Registrant)

June 15, 2000 By:

                           ---------------------------
                          David M. Mott, Vice Chairman
                           and Chief Financial Officer
[{"type": "8-K", "sequence": "1", "filename": "0001.txt", "description": "MEDIMMUNE & MEDAREX ENTER ANTIBODY AGREEMENT", "secsgml_size_bytes": 4279}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "656127"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
MEDIMMUNE AND MEDAREX ENTER BROAD ANTIBODY AGREEMENT

Gaithersburg,  MD and Princeton,  NJ, June 13, 2000 -- MedImmune,  Inc. (NASDAQ:
MEDI) and Medarex, Inc. (NASDAQ:  MEDX) announced today that they have signed an
agreement to develop fully human antibodies to multiple antigens using Medarex's
HuMAb-Mouse(R) technology. Under the terms of the agreement,  MedImmune receives
an exclusive,  worldwide license for the use of Medarex's HuMAb-Mouse technology
for the development of antibodies against respiratory  syncytial virus (RSV) and
an option to further license the use of this technology for additional antigens.
Medarex  receives  technology  access  fees and could also  receive  license and
milestone payments, as well as royalties on product sales.

"We are excited about the opportunity to use Medarex's HuMAb-Mouse technology to
evaluate new antibodies for potential  product  development,"  said Dr. Wayne T.
Hockmeyer, MedImmune's chairman and chief executive officer.

"We are extremely  pleased to add  MedImmune to our growing list of  HuMAb-Mouse
partners,"  said Donald L.  Drakeman,  Medarex's  president and chief  executive
officer.  "MedImmune's proven product development  capabilities are a good match
for our HuMAb-Mouse technology."

Medarex is a  biopharmaceutical  company  developing  monoclonal  antibody-based
therapeutics  to  fight  cancer  and  other  life-threatening  and  debilitating
diseases.  Medarex has assembled a broad platform of patented  technologies  for
antibody  discovery  and  development,   including  the  HuMAb-Mouse(R)  and  TC
Mouse(TM)  systems for the creation of  high-affinity,  fully human  antibodies;
T-12  Development(TM)  offering the capability of moving from target to trial in
approximately  12  months;   and  Trans-Phage   Technology(TM)   combining  high
throughput screening with fully human antibody development.  Medarex creates and
develops fully human antibodies for itself and others,  offering a full range of
antibody   development   capabilities,   including   pre-clinical  and  clinical
manufacturing services. For more information about Medarex visit its web site at
www.medarex.com.

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  the  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

Except for the historical  information  presented,  certain matters discussed in
this press release are  forward-looking  statements  that are subject to certain
risks and  uncertainties  that could cause actual  results to differ  materially
from any future  results,  performance or  achievements  expressed or implied by
such  statements.  Such risks and  uncertainties  include risks  associated with
product discovery and development as well as risks detailed from time to time in
the companies' public disclosure  filings with the U.S.  Securities and Exchange
Commission  (SEC),  including each company's  Annual Report on Form 10-K for the
fiscal year ended December 31, 1999.  Copies of public  disclosure  filings with
the Securities and Exchange  Commission  (SEC) are available from each company's
investor relations  department.  There can be no assurance that such development
efforts  will  succeed,  that such  products  will receive  required  regulatory
clearance  or  that,  even if such  regulatory  clearance  were  received,  such
products would ultimately achieve commercial success.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereonto duly authorized.

                                 MEDIMMUNE, INC.
                                -----------------
                                  (Registrant)

June 15, 2000 By:

                           ---------------------------
                          David M. Mott, Vice Chairman
                           and Chief Financial Officer